Previous 10 | Next 10 |
The U.S. Food and Drug Administration (FDA) granted rare pediatric disease designation to Avrobio's ( NASDAQ: AVRO ) gene therapy AVR-RD-04 to treat cystinosis. Cystinosis is a rare, multisystem genetic disorder characterized by the excess build up of an amino acid cal...
Second AVROBIO gene therapy program that has been granted rare pediatric disease designation by FDA AVR-RD-04 has previously received orphan drug designation from FDA and EMA AVROBIO, Inc . (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to ...
Avrobio ( NASDAQ: AVRO ) said its autologous hematopoietic stem cell (HSC) gene therapy AVR-RD-05 was cleared to enter a phase 1/2 trial in U.K. to treat infants with neuronopathic mucopolysaccharidosis type II (nMPS-II) or Hunter syndrome. nMPS-II is a rare genetic meta...
First in-human pediatric Phase 1/2 study to evaluate the safety and tolerability of first-in-class gene therapy targeting infants age ≥3 months and ≤12 months, diagnosed with nMPS-II University of Manchester (U.K.) expects to initiate clinical trial later this ye...
Summary Shares have fallen by 30% so far in 2022. Durability and safety for the Fabry disease gene therapy program continues to look best-in-class and enrollment should accelerate due to investigator enthusiasm. Excitement is palpable for CAR-Treg programs as renal transplant ...
AVROBIO, Inc . (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that members of its senior management team are scheduled to participate in four upcoming investor conferences: Citi's 17 th...
AVROBIO press release ( NASDAQ: AVRO ): Q2 GAAP EPS of -$0.64 misses by $0.09 . As of June 30, 2022, AVROBIO had $132.4 million in cash and cash equivalents, as compared to $189.6 million in cash and cash equivalents as of December 31, 2021. For further details s...
Presented positive data from first five patients in Phase 1/2 cystinosis trial 1 showing systemic gene therapy effect at the American Society of Gene and Cell Therapy Annual Meeting; all five patients remain off oral cysteamine Comprehensive Gaucher disease fra...
AVROBIO, Inc . (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced that members of its senior management team are scheduled to participate in two upcoming investor conferences: H...
The shares of gene therapy company AVROBIO ( NASDAQ: AVRO ) jumped ~9% in the pre-market Monday after the company announced that the FDA awarded the orphan drug designation for AVR-RD-05, a gene therapy candidate for mucopolysaccharidosis type II (MPSII), or Hunter syndrom...
News, Short Squeeze, Breakout and More Instantly...
2024-06-20 09:02:05 ET AvroBio Inc (AVRO) announced stock split at a ratio of 1-for-12 on 2024-06-21 ... Full story available on KlickAnalytics.com
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...
Swire Pacific Ltd. ADR (Class A) (SWRAY) is expected to report for Q4 2023 Troika Media Group Inc. (TRKAQ) is expected to report for quarter end 2023-12-31 American Environmental Partners Inc. (AEPT) is expected to report for quarter end 2023-12-31 Veolia Environnement S.A. ADR (VEOEY...